Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Check-Cap Ltd Ord (NQ: CHEK )

1.250 USD +0.100 (+8.70%)
Official Closing Price Updated: 7:58 PM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Check-Cap Ltd Ord

< Previous 1 2 3 Next >
Check-Cap Issues Letter to Shareholders
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly... 
From PR Newswire
Thinking about buying stock in 3D Systems, Nio, Orchard Therapeutics, Check Cap, or Gevo?
InvestorsObserver issues critical PriceWatch Alerts for DDD, NIO, ORTX, CHEK, and GEVO. 
From PR Newswire
Thinking about buying stock in Aileron Therapeutics, Check Cap, Jaguar Health, Clearside Biomedical, or Gritstone Oncology?
InvestorsObserver issues critical PriceWatch Alerts for ALRN, CHEK, JAGX, CLSD, and GRTS. 
From PR Newswire
Thinking about buying stock in Zomedica, Check Cap, Jaguar Health, Vale SA, or Workhorse Group?
InvestorsObserver issues critical PriceWatch Alerts for ZOM, CHEK, JAGX, VALE, and WKHS. 
From PR Newswire
Check-Cap Reports Third Quarter 2020 Financial Results and Corporate Highlights
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly... 
From PR Newswire
Check-Cap Reports Second Quarter 2020 Financial Results and Corporate Highlights
IDE submission to the FDA for C-Scan® planned for the end of 2020; Initiation of a U.S. pivotal study planned for 2021 
From PR Newswire
Institutional Ownership Bullish On These US Stocks: $CHEK $OCGN $SNCA
Tags The Market Signal
From The Market Signal
Check-Cap Announces Exercise of Warrants For $9.6 Million Gross Proceeds
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan®, the first and only patient-friendly... 
From PR Newswire
Check-Cap Announces Receipt of Nasdaq Minimum Bid Price Notification
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free ingestible capsule... 
From PR Newswire
Check-Cap Reports First Quarter 2020 Financial Results and Provides Corporate Update
Strengthened balance sheet through a total of $16.3 million in registered direct offerings and a private placement of ordinary shares in the first half of 2020 
From PR Newswire
Check-Cap Ltd. Announces $3.0 Million Registered Direct Offering
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free... 
From PR Newswire
Check-Cap Ltd. Announces $4.5 Million Registered Direct Offering
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free... 
From PR Newswire
Check-Cap Ltd. Announces $4.0 Million Registered Direct Offering
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free... 
From PR Newswire
Check-Cap Provides Update on COVID-19 Pandemic Impact on Operational and Clinical Activities
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free... 
From PR Newswire
Check-Cap Reports Fourth Quarter and Full Year 2019 Financial Results
Company planning to initiate a U.S. pivotal study of the C-Scan System in late 2020 
From PR Newswire
Check-Cap Announces Positive Results from U.S. Pilot Study of C-Scan® System
Advancing towards IDE submission to the FDA, targeting initiation of U.S. pivotal study in late 2020 
From PR Newswire
Check-Cap Announces $4.75 Million Private Placement
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first... 
From PR Newswire
Check-Cap Reports Third Quarter 2019 Financial Results and Corporate Highlights
Successfully launched U.S. pilot study and reported positive final results from post-CE approval study of the C-Scan® System 
From PR Newswire
Check-Cap to Present at the Dawson James 5th Annual Small Cap Growth Conference
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first... 
From PR Newswire
Check-Cap Expands Leadership Team With Appointment of Dr. Vardit Segal as Vice President of Clinical Affairs
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first... 
From PR Newswire
Check-Cap to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of the C-Scan® System, the first... 
From PR Newswire
Check-Cap and GE Healthcare Announce Completion of Manufacturing Line Transfer Implementation and Qualification for the C-Scan® System Operated by GE Healthcare
GE Healthcare facility in Chicago to support clinical investigation needs of the C-Scan® System in the U.S. 
From PR Newswire
Check-Cap Reports Second Quarter 2019 Financial Results and Corporate Highlights
Reported positive final results from post-CE approval study of the C-Scan® System 
From PR Newswire
Thinking about buying stock in Beyond Meat, Check-Cap, Micron Technology, Netflix, or Uber Technologies?
InvestorsObserver issues critical PriceWatch Alerts for BYND, CHEK, MU, NFLX, and UBER. 
From PR Newswire
Check-Cap Announces Positive Final Results from Its Post-CE Approval Study of the C-Scan® System
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only... 
From PR Newswire
Check-Cap Appoints Joshua (Shuki) Belkar as Vice President of Operations
Mr. Belkar Brings More Than 20 Years of Global Medical Device Experience, Including at Medtronic and Mazor Robotics 
From PR Newswire
Check-Cap to Present Data at Digestive Disease Week® Demonstrating Substantial Improvement in Precancerous Polyp Detection
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only... 
From PR Newswire
Check-Cap Reports First Quarter 2019 Financial Results
Initiates U.S. pilot study of C-Scan® at NYU School of Medicine and Mayo Clinic 
From PR Newswire
Check-Cap Announces Second Trial Site Joins Ongoing U.S. Pilot Study of C-Scan®
Mayo Clinic joins New York University in pilot study of C-Scan® in the U.S. 
From PR Newswire
Analysis: Positioning to Benefit within CRISPR Therapeutics AG, SPIRIT MTA REIT, Gaia, Perceptron, Check-Cap, and Key Tronic — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CRISPR Therapeutics AG... 
From GlobeNewswire News Releases
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.